Hemodynamic monitoring company LiDCO said that its latest cardiac output monitor with non-invasive technology had received regulatory approval for commercial sale in China. The Chinese Food and Drug Administration formally approved the company's hemodynamic LiDCOrapidv3 monitor product. It would be sold via LiDCO's distribution partner, Beijing Gloryway Medical, a medical device sales group specialising in anaesthesia and patient monitoring. At 1:57pm: (LON:LID) LiDCO Group PLC share price was +0.65p at 5.1p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.